Human medicines European public assessment report (EPAR): Voydeya, danicopan, Date of authorisation: 19/04/2024, Revision: 3, Status: Authorised

Article 57 product data

Joint Heads of Medicines Agencies (HMA)/European Medicines Agency (EMA) multistakeholder workshop on Patient Registries for Alzheimer's disease, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 December 2025, 09:00 (CET) to 15 December 2025, 17:30 (CET)

Human medicines European public assessment report (EPAR): Entresto, sacubitril,valsartan, Date of authorisation: 19/11/2015, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Neparvis, sacubitril,valsartan, Date of authorisation: 26/05/2016, Revision: 26, Status: Authorised

EMA/PE/0000232896

EMEA-000976-PIP01-10

Opinion/decision on a Paediatric investigation plan (PIP): Zeposia, Ozanimod (hydrochloride), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0131/2022

Human medicines European public assessment report (EPAR): Celsentri, maraviroc, Date of authorisation: 18/09/2007, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Hetronifly, serplulimab, Date of authorisation: 03/02/2025, Revision: 4, Status: Authorised